Microbot Medical Inc. Receives FDA 510(k) Clearance for LIBERTY® Endovascular Robotic System, Prepares for Q4 Commercial Launch

Reuters10-16
<a href="https://laohu8.com/S/MBOT">Microbot Medical Inc</a>. Receives FDA 510(k) Clearance for LIBERTY® Endovascular Robotic System, Prepares for Q4 Commercial Launch

Microbot Medical Inc. has announced that it recently received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. This regulatory approval allows the company to move forward with its commercial launch plans, including exhibiting the system at the upcoming Symposium on Clinical Interventional Oncology. The clearance was granted solely to Microbot Medical Inc., and the company has also completed recruitment of its commercial leadership team in preparation for a limited market launch later this quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546625-en) on October 16, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment